Shinya Bio Successfully Closes Series A Funding to Accelerate Industrialization of 'Hua Shu' Recombinant Collagen Products

A Leader in China’s Recombinant Collagen Industry—Xiangya Biomedicine (Huzhou) Co., Ltd. (hereinafter referred to as “Xiangya Biomedicine”) Has Successfully Completed Its Series A Financing Round, with Hainan Anrui No. 1 Venture Capital Fund Partnership, Hainan Anrui Private Equity Fund Partnership, and Huzhou Jinkun Equity Investment Partnership (a subsidiary of Sci-Tech Innovation Investment Group) Investing a Total of Nearly RMB 100 Million.This marks another significant milestone for the company following Mylike Medical Group’s strategic investment in Xiangya Biomedicine in April 2024.

Xiangya Biomedicine focuses on the R&D of innovative medical devices and new drugs in fields such as wound repair, medical aesthetics, and serious medical care. Centered on synthetic biology and stem cell technologies, it prioritizes various regenerative materials, including recombinant collagen. The company is dedicated to the R&D and industrialization of Class II/III medical devices and cellular products featuring recombinant collagen for the medical aesthetics sector (wound repair, scar prevention, implantable fillers) and the serious medical sector (artificial skin, cultured cartilage, cardiovascular stents).

Currently, its “Hua Shu” series of recombinant collagen products, such as liquid dressings and scar gels, have been applied in multiple clinical areas—including diabetic foot ulcers, radiation dermatitis, cesarean section scar repair, and post-procedural skin repair following various medical aesthetic treatments—demonstrating favorable efficacy.

Mr. Liu Yang, General Manager of Xiangya BiomedicineIt was stated that the funds from this financing round will be applied to in-depth R&D and industrialization of the company’s “Huashu” series of recombinant collagen products, with a particular focus on accelerating the capacity expansion of its proprietary “triple-helix structure” recombinant collagen, as well as advancing regulatory submissions and clinical trials for numerous Class III medical devices, thereby further consolidating the company’s leading position among domestic peers.

Xiangya Biomedicine is led by a Nobel Laureate in Physiology or Medicine and co-founded by experts from renowned domestic and international institutions, including the Chinese Academy of Sciences and the University of Macau. The company is dedicated to the research, development, and industrialization of third-generation recombinant collagen-based novel biomaterials. It has undertaken multiple key innovation projects at the national, provincial, and municipal levels, holds numerous product patents and R&D achievements, and has established long-term strategic partnerships with many brands and large medical institutions both in China and abroad.

The company possesses capabilities in the R&D of innovative raw materials, the R&D and manufacturing of medical devices, and cosmetic OBM services, while leveraging key technologies such as drug screening, nano-encapsulation, lyophilization of active substances, and exosome preparation.

As a leading domestic technology innovation enterprise in the fields of regenerative medicine and anti-aging, its "Huashu" brand has experienced rapid growth in recent years. It has achieved continuous breakthroughs in the research and development of innovative medical devices and new drugs across areas such as wound repair, medical aesthetics, and serious medical care. Centered on the Taihu Institute of Regenerative Medicine as its core R&D platform, the company has launched multiple flagship products under the "Huashu" name. Among these, its series of scar gel, liquid dressings, and repair patches have gained widespread recognition and acclaim within the industry.

Hainan Anrui Private Equity Fund Partnership (Limited Partnership) is a venture capital fund registered in the Hainan Free Trade Port and filed with the Asset Management Association of China. The fund manager is Haisheng Private Equity Fund Management (Hainan) Co., Ltd. Haisheng Fund specializes in private equity investment and venture capital fund business, with assets under management exceeding RMB 1 billion. Its investment portfolio spans multiple high-growth sectors, including new energy, information technology, advanced manufacturing, and biopharmaceuticals, and it has successfully identified and invested in numerous high-potential enterprises.

Huzhou Nan Taihu Science and Technology Innovation Investment Development Group Co., Ltd. (hereinafter referred to as the “Sci-Tech Innovation Investment Group”) is a municipal-level, wholly state-owned enterprise established with 100% capital contribution from the Huzhou State-owned Assets Supervision and Administration Commission, with a registered capital of RMB 3 billion. Leveraging the high-level platform of the Huzhou Nan Taihu New Area, one of the first four new areas in Zhejiang Province, the Group focuses on its core businesses of industrial investment and fund investment, providing full-lifecycle fund investment services to various industrial entities in the Nan Taihu New Area.

To date, the Sci-Tech Venture Capital Group and its subsidiaries have partnered with multiple leading domestic institutions, jointly operating more than 20 industrial funds with a total scale of RMB 21 billion.